Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Published on 27 Nov 2024

Abscopal effect-induced spontaneous regression of distant metastases in malignant mesenchymal tumor: a case report

in Cancer Immunity and Immunotherapy

Meltem Kirli Bolukbas
Cemile Ozdemir
Esengul Kocak Uzel

Frontiers in Oncology

doi 10.3389/fonc.2024.1475129

384 views

Case Report

Published on 26 Nov 2024

Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review

in Cancer Immunity and Immunotherapy

Yinfang Gu
Lilan Yi
Xiaofang Zou
Longhua Guo
Guowu Wu
Jingjing Zhao

Frontiers in Oncology

doi 10.3389/fonc.2024.1442605

739 views

Original Research

Published on 25 Nov 2024

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy

in Cancer Immunity and Immunotherapy

Anna Rudzińska
Pola Juchaniuk
Jakub Oberda
Kamila Krukowska
Sylwia Krzyśkowska
Eliza Kuchta
Anna Rodzajewska
Mariola Janiszewska
Katarzyna Szklener
Katarzyna Machulska-Ciuraj

Frontiers in Oncology

doi 10.3389/fonc.2024.1459608

628 views

Review

Published on 25 Nov 2024

Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy

in Cancer Immunity and Immunotherapy

Xiangyu Yin
Yunjie Song
Wanglong Deng
Neil Blake
Xinghong Luo
Jia Meng

Frontiers in Oncology

doi 10.3389/fonc.2024.1483454

1,174 views

Original Research

Published on 25 Nov 2024

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching

in Cancer Immunity and Immunotherapy

Zeyang Wang
Bingnan Ren
Haotian Yang
Xuejia Qiu
Yin Wu
Chaojun Xue
Yue Zhao
Xiao Li
Ze Yu
Jinyuan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1446950

737 views

Original Research

Published on 20 Nov 2024

Evening cortisol levels are prognostic for progression-free survival in a prospective pilot study of head and neck cancer patients

in Cancer Immunity and Immunotherapy

Elizabeth Cash
Isak Beck
Brooks Harbison
Christy Albert
Sandra E. Sephton

Frontiers in Oncology

doi 10.3389/fonc.2024.1436996

1,029 views

Review

Published on 19 Nov 2024

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

in Cancer Immunity and Immunotherapy

Jian Xu

Frontiers in Oncology

doi 10.3389/fonc.2024.1491099

970 views

Editorial

Published on 19 Nov 2024

Editorial: Cell death in cancer immunology

in Cancer Immunity and Immunotherapy

Laura Mondragón
Shensi Shen
Laura Senovilla

Frontiers in Oncology

doi 10.3389/fonc.2024.1504738

587 views

Original Research

Published on 12 Nov 2024

Characterization of the T-cell receptor repertoire associated with lymph node metastasis in colorectal cancer

in Cancer Immunity and Immunotherapy

Ya’nan Zhen
Hong Wang
Runze Jiang
Fang Wang
Cunbao Chen
Zhongfa Xu
Ruixue Xiao

Frontiers in Oncology

doi 10.3389/fonc.2024.1354533

594 views

Original Research

Published on 11 Nov 2024

CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer

in Cancer Immunity and Immunotherapy

Xiaolin Lu
Li-Ping Ge
Zhaopei Liu
Yu Zhu
Dingwei Ye
Yuan Chang

Frontiers in Oncology

doi 10.3389/fonc.2024.1498579

1,868 views

Case Report

Published on 11 Nov 2024

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review

in Cancer Immunity and Immunotherapy

Qiu Zhao
Min Xiao
Jian Ma
Cong Fu
Qianqian Gao

Frontiers in Oncology

doi 10.3389/fonc.2024.1465664

882 views

Review

Published on 07 Nov 2024

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

in Cancer Immunity and Immunotherapy

Yifei Ge
Lixue Jiang
Chengru Yang
Qingfu Dong
Chengwu Tang
Yi Xu
Xiangyu Zhong

Frontiers in Oncology

doi 10.3389/fonc.2024.1449696

1,867 views

Original Research

Published on 04 Nov 2024

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

in Cancer Immunity and Immunotherapy

Yongwei Cheng
Zihao Song
Ye Liu
Xichao Xu
Dali Zhang
Yigui Zou
Liang Liu
Yinzhen Zeng
Wenwen Li
Daming Bai

Frontiers in Oncology

doi 10.3389/fonc.2024.1442221

1,400 views

Review

Published on 31 Oct 2024

Landscape of targeted therapies for lung squamous cell carcinoma

in Cancer Immunity and Immunotherapy

Qiuxuan Chen
Xiaoshuo Zheng
Jian Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1467898

1,593 views

Review

Published on 29 Oct 2024

Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

in Cancer Immunity and Immunotherapy

Meng-Han Huo
Yilinuer Adeerjiang
Ayiguzhali Abulitipu
Umair Khan
Xin-Xi Li
Lei Zhang
Ye Tian
Sheng Jiang
Can-Can Xu
Xian-Zhen Chao

Frontiers in Oncology

doi 10.3389/fonc.2024.1325575

1,444 views

Original Research

Published on 29 Oct 2024

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

in Cancer Immunity and Immunotherapy

Toshio Shimizu
John Powderly
Albiruni Abdul Razak
Patricia LoRusso
Kathy D. Miller
Steven Kao
Sarah Kongpachith
Catherine Tribouley
Michelle Graham
Brian Stoll

Frontiers in Oncology

doi 10.3389/fonc.2024.1376551

2,641 views

Navigation group

Articles

Abscopal effect-induced spontaneous regression of distant metastases in malignant mesenchymal tumor: a case report

Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy

Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching

Evening cortisol levels are prognostic for progression-free survival in a prospective pilot study of head and neck cancer patients

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

Editorial: Cell death in cancer immunology

Characterization of the T-cell receptor repertoire associated with lymph node metastasis in colorectal cancer

CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

Landscape of targeted therapies for lung squamous cell carcinoma

Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors